Adjuvant therapy in renal cell carcinoma: the perspective of urologists
ConclusionsA minority of urologists would use AT and are more confident in ASSURE-trial. Reluctance of prescribing AT mainly is based on lack of OS data and conflicting trial results.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Carcinoma | Conferences | Germany Health | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology